Taro gets FDA approval for biogeneric epilepsy drug

Industry sources: levetiracetam tablets had over $700 million in US sales in 2009.

2 February 10 15:46, Globes' correspondent

Taro Pharmaceutical Industries Ltd. (Pink Sheets: TAROF) has received US Food and Drug Administration (FDA) approval for the company's Abbreviated New Drug Application (ANDA) for Levetiracetam tablets, a biogeneric version of Belgian biopharmaceutical company UCB SA's (Euronext: UCB) Keppra tablets for the treatment of epilepsy.

Taro received FDA approval for four dosages of the tablets: 250 mg, 500 mg, 750 mg, and 1000 mg. According to industry sources, levetiracetam tablets had over $700 million in US sales in 2009.

Taro's share closed at $10.01 on Wall Street yesterday.

Published by Globes [online], Israel business news - www.globes-online.com - on February 2, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010